Pipeline
We currently are developing a portfolio of four product candidates, including three product candidates in clinical development and one product candidate in IND-track development. Our pipeline addresses diseases that are not well served by currently available therapies and represent large potential commercial opportunities. We believe that our product candidates offer innovative therapeutic approaches and may provide significant advantages relative to current therapies.
Our most advanced product candidates include pimavanserin in Phase III development for Parkinson's disease psychosis in collaboration with Biovail, AGN XX/YY in Phase II for chronic pain and AC-262271 in Phase I for glaucoma, both in collaboration with Allergan, and AM-831 in IND-track development in collaboration with Meiji Seika.
Please click on the sub-links to this page to learn more about our product candidates and the targeted disease areas.
back to top